Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma

Nobuaki Matsubara,Junji Yonese,Takahiro Kojima,Haruhito Azuma,Hiroaki Matsumoto,Thomas Powles,Jonathan E. Rosenberg,Daniel P. Petrylak,Maria Matsangou,Chunzhang Wu,Mary Campbell, Mayumi Yamashiro

Cancer Medicine（2022）

引用 7|浏览7

暂无评分

摘要

This subgroup analysis confirmed that EV, with consistent efficacy and safety/tolerability in the EV-301 Japanese subgroup and overall study population, represents an important treatment option for previously treated patients with la/mUC.

查看译文

关键词

Japanese,antibody-drug conjugate,enfortumab vedotin,metastatic,urothelial carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要